非洲女性瘤学家面临的挑战:一种混合方法研究
Miriam Mutebi1, Naa Adorkor Aryeetey2, Haimanot Kasahun Alemu3
1Surgery, Aga Khan University, Nairobi County, Nairobi, Kenya.
BMJ oncology
|January 31, 2025
概括
非洲的女性瘤科医生面临着巨大的工作与生活平衡和社会义务压力,以及独特和共同的挑战. 解决方案包括提高工作灵活性和指导,以赋予瘤学女性医生权力.
科学领域:
- 在瘤学瘤学.
- 医学中的性别研究.
- 全球健康 全球健康
背景情况:
- 之前的研究强调了西方国家女性瘤学家面临的挑战.
- 有限的研究已经探索了非洲女性瘤学家的经历.
研究的目的:
- 确定非洲女性瘤学家面临的共同和重大挑战.
- 探索潜在的解决方案,以改善他们的专业经验.
主要方法:
- 一个德尔菲共识过程,涉及来自20个非洲国家的29名女性瘤学家.
- 聚焦小组讨论以详细阐述所识别的挑战和解决方案.
- 描述性统计和收集数据的主题分析.
主要成果:
- 在非洲,女性瘤学家在个人,人际,机构和社会层面面面临着挑战.
- 确定的主要挑战是平衡工作-家庭需求和社会义务.
- 一些挑战反映了其他地区的挑战,而另一些则是特定于非洲背景的.
结论:
- 非洲的女性瘤学家在社会生态框架内面临着多方面的挑战.
- 通过增加人数和领导角色赋权至关重要.
- 为了改变政策,需要性别敏感的教育和系统对话.
相关概念视频
Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Cancer Survival Analysis
863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863


